Skip to content Skip to content

Press Releases


Filter Releases
 
INCLINE VILLAGE, Nev., Aug. 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2017 including: Total revenues of $143.8 million and $189.3 million for the three and six months ended June 30, 2017, respectively. GAAP diluted EPS of $0.39...
INCLINE VILLAGE, Nev., July 31, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2017, on Thursday, August 3, 2017, after market close. PDL's management will host a conference call and webcast that day at 4:30...
INCLINE VILLAGE, N.V., June 5, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its subsidiary, Noden Pharma DAC (Noden), received a Paragraph IV Notice Letter advising that Anchen Pharmaceuticals, Inc. (Anchen) submitted an Abbreviated New Drug Application ("ANDA") to the United States Food and Drug Administration...
INCLINE VILLAGE, Nev., June 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia, the company's vice president and chief financial officer, will present at the Jefferies 2017 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Friday, June 9, 2017 at 8:30...
ORLANDO, Fla., and INCLINE VILLAGE, Nev., May 11, 2017 /PRNewswire/ -- LENSAR, Inc. (LENSAR), a global leader in next generation femtosecond laser technology for refractive cataract surgery, and PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the completion of LENSAR's financial restructuring with a court-approved exit plan finalized on Ma...
INCLINE VILLAGE, Nev., May 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including: Total revenues of $45.4 million for the three months ended March 31, 2017. GAAP diluted EPS of $0.04 for the three months ended March 31, 2017...
INCLINE VILLAGE, Nev., April 26, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 3, 2017, after market close. PDL's management will host a conference call and webcast that day at ...
INCLINE VILLAGE, Nev., April 24, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017, the Company entered into a settlement agreement with certain subsidiaries of Merck & Co., Inc. ("Merck") to resolve the patent infringement lawsuit between the parties pending in the U.S. District Cou...
INCLINE VILLAGE, Nev., April 6, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June 9, 2017, at 10:00 a.m. Pacific Time for all stockholders of record on April 17, 2017. The meeting will take place at the Hyatt Regency Hotel in Inc...
INCLINE VILLAGE, Nev., March 14, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at the Oppenheimer 27th Annual Healthcare Conference next week in New York. The session will be webcast live and will occur on Tuesday, March 21, 2017 at 8:...
INCLINE VILLAGE, Nev., March 2, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in March. Cowen and Company 37th Annual Health Care ConferenceWednesday, March 8, 2017, 8:00 a.m. ESTBoston, MA 29t...
INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2016 including: Total revenues of $66.5 million and $244.3 million for the three and twelve months ended December 31, 2016, respectively. GAAP...
INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that the company's board of directors has authorized the repurchase of up to $30 million of the company's common stock through March 2018.  Purchases may be made in open-market transactions, block transactions on or off an exchange, in priv...
INCLINE VILLAGE, Nev., Feb. 22, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2016 financial results for the period ended December 31, 2016, on Wednesday, March 1, 2017, after market close. PDL's management will host a conference call and webca...
INCLINE VILLAGE, Nev., Feb. 17, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will participate in a fireside chat at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York. The session will be webcast live and will occur on...
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due December 1, 2021 (2021 Notes).  PDL issued $150.0 million aggregate principal amount of 2021 Notes.  In addition, PDL has granted the underwriters an...
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, Novemb...
INCLINE VILLAGE, Nev., Nov. 17, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering.  The conversion rate of the Notes will initially be 262.2951 shares of commo...
INCLINE VILLAGE, Nev., Nov. 15, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the Notes) under PDL's shelf registration statement filed with the U.S. Securiti...
INCLINE VILLAGE, Nev., Nov. 3, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2016 including: Total revenues of $53.6 million and $177.8 million for the three and nine months ended September 30, 2016, respectively. GAAP diluted EP...
INCLINE VILLAGE, Nev., Oct. 27, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2016 financial results for the period ended September 30, 2016, on Thursday, November 3, 2016, after market close. PDL's management will host a conference call and webcast that ...
INCLINE VILLAGE, Nev., Aug. 29, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of $54.7 million as ...
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2016 including: Total revenues of $21.0 million and $124.2 million for the three and six months ended June 30, 2016, respectively. GAAP diluted EPS of $0.03...
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend. John P. McLaughlin, president and chief executive officer of PDL, stated, "Since 2009, our dividends have been an important element of ou...
INCLINE VILLAGE, Nev., Aug. 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreeme...
INCLINE VILLAGE, Nev., July 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at...
INCLINE VILLAGE, Nev., July 6, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has completed an initial equity investment of $75 million in Noden Pharma DAC (Noden), a new privately-held company domiciled in Ireland, and an affiliate.  Noden today announced that it closed its transaction relating to a purchase...
INCLINE VILLAGE, Nev., June 13, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has paid the June 13, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of June 6, 2016, the record date. About PDL BioPharma PDL manages a portfolio of pat...
INCLINE VILLAGE, Nev., June 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:...
INCLINE VILLAGE, Nev., May 24, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sel...
INCLINE VILLAGE, Nev., May 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2016 including: Total revenues of $103.1 million for the first quarter of 2016. Non-GAAP diluted earnings per share (EPS) of $0.52 increased approximately 11 percent versus...
INCLINE VILLAGE, Nev., May 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016.  The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter d...
INCLINE VILLAGE, Nev., April 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Easte...
INCLINE VILLAGE, Nev., March 31, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 2, 2016, at 10:00 a.m. Pacific Time for all stockholders of record on April 8, 2016. The meeting will take place at the Hyatt Regency Hotel in I...
INCLINE VILLAGE, Nev., March 14, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of March 4, 2016, the record date. About PDL BioPharmaPDL manages a portfolio of patents and royalty ass...
INCLINE VILLAGE, Nev., March 2, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference next week in Boston. The presentation will be webcast live and will occur on Wednesday, M...
INCLINE VILLAGE, Nev., Feb. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and twelve months ended December 31, 2015. Total revenues in 2015 increased two percent to $590.4 million from $581.2 million in 2014. Revenues for the year ended December 31, 2015 included $4...
INCLINE VILLAGE, Nev., Feb. 17, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 RBC Capital Markets' Healthcare Conference next week in New York City. The presentation will be webcast live and will occur on Wednesday,...
INCLINE VILLAGE, Nev., Feb. 16, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2015 financial results for the period ended December 31, 2015, on Monday, February 22, 2016, after market close. PDL's management will host a conference call and webcast that da...
INCLINE VILLAGE, Nev., Feb. 2, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 201...
INCLINE VILLAGE, Nev., Feb. 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016.  The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter divid...
INCLINE VILLAGE, Nev., Dec. 17, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the closing of the previously announced acquisition of substantially all of LENSAR, Inc.'s (LENSAR) assets by a wholly-owned subsidiary of ALPHAEON Corporation. As part of this acquisition, ALPHAEON's subsidiary entered into an amended and ...
INCLINE VILLAGE, Nev., Dec. 14, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 4, 2015, the record date. About PDL BioPharmaPDL manages a portfolio of patents an...
INCLINE VILLAGE, Nev., Dec. 2, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today acknowledges receipt of $133.7 million in notable cash payments from November 1, 2015 through December 1, 2015. PDL does not typically report individual payments such as these, but given the interest relating to some of these payments, the company dec...
INCLINE VILLAGE, Nev., Nov. 24, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 27th Annual Piper Jaffray Healthcare Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, D...
INCLINE VILLAGE, Nev., Nov. 16, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced recent developments related to its debt investment in LENSAR, Inc. (LENSAR), a leading global developer and manufacturer of Femtosecond Cataract Lasers.  As announced by ALPHAEON Corporation (ALPHAEON), a definitive agreement between a subs...
INCLINE VILLAGE, Nev., Nov. 11, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference in London, England.  The presentation will be webcast live and will occur on Wednesday, Nov...
INCLINE VILLAGE, Nev., Nov. 6, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) issued financial results for the third quarter on Wednesday, November 4, 2015 and has subsequently received numerous inquiries on its reported royalties from royalty rights it acquired from Depomed, Inc. (Depomed).  Specifically, the nature of the questions...
INCLINE VILLAGE, Nev., Nov. 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2015. Total revenues were $124.6 million for the three months ended September 30, 2015, compared to $164.6 million for the same period of 2014, and $412.4 mil...
INCLINE VILLAGE, Nev., Oct. 28, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2015 financial results for the period ended September 30, 2015, on Wednesday, November 4, 2015, after market close. PDL's management will host a conference call and webcast tha...
INCLINE VILLAGE, Nev., Sept. 23, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has received approximately $21.4 million in connection with the termination of PDL's structured financing agreement with Avinger, Inc. (NASDAQ: AVGR), which included repayment of the full principal amount outstanding of $20.6 mill...
INCLINE VILLAGE, Nev., Sept. 21, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (Nasdaq: PDLI) announced today that it has acquired a portion of the royalties on expected sales of AcelRx Pharmaceuticals Inc.'s ("AcelRx") (Nasdaq: ACRX) Zalviso™ (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its com...
INCLINE VILLAGE, Nev., Sept. 16, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) today announced that Samuel R. Saks, M.D. has been appointed to the company's board of directors. Dr. Saks serves as a board member for several biotechnology and pharmaceutical companies. Dr. Saks brings over 35 years of biotechnology management ...
INCLINE VILLAGE, Nev., Sept. 14, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 4, 2015, the record date. About PDL BioPharma PDL manages a portfolio of patent...
INCLINE VILLAGE, Nev., Sept. 10, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 6th Annual Credit Suisse US Small & Mid Cap Conference in New York City next week. The group presentation will occur on Thursday, September 1...
INCLINE VILLAGE, Nev., Sept. 8, 2015 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) today announced that Paul R. Edick has been appointed to the company's board of directors. Mr. Edick is currently managing partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. Mr. Edick ...
INCLINE VILLAGE, Nev., Aug. 5, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2015. Total revenues were $138.1 million for the three months ended June 30, 2015, compared to $162.8 million for the same period of 2014, and $287.8 million for t...
INCLINE VILLAGE, Nev., July 29, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) with up to $200 million in revenue interest financing in exchange for royalties on the...
INCLINE VILLAGE, Nev., July 28, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2015 financial results for the period ended June 30, 2015, on Wednesday, August 5, 2015, after market close. PDL's management will host a conference call and webcast that day ...
INCLINE VILLAGE, Nev., June 29, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has entered into a credit agreement with CareView Communications, Inc. (OTCQB: CRVW) whereby PDL will provide CareView with up to $40 million of secured debt financing. CareView is an information technology provider to the healthcare indu...
INCLINE VILLAGE, Nev., June 25, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Nasdaq 32nd Investor Program in London, England.  The fireside chat-style of presentation will be webcast and will occur on Tuesday, June 30, ...
INCLINE VILLAGE, Nev., June 24, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has appointed Steffen Pietzke, CPA, to the position of controller and chief accounting officer. Mr. Pietzke officially joins the company this week. "Steffen is an excellent addition to PDL and brings over 14 years of...
INCLINE VILLAGE, Nev., June 15, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2015, the record date. About PDL BioPharmaPDL manages a portfolio of patents and royalt...
INCLINE VILLAGE, Nev., May 27, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference next week in New York City.  The presentation, which will be webcast, will occur on Wednesday, June...
INCLINE VILLAGE, Nev., May 6, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2015. Total revenues for the first quarter of 2015 increased nine percent to $149.7 million from $136.8 million in the first quarter of 2014. Revenues for the quarter ended March ...
INCLINE VILLAGE, Nev., April 29, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2015 financial results for the period ended March 31, 2015, on Wednesday, May 6, 2015, after market close. PDL's management will host a conference call and webcast that day at...
INCLINE VILLAGE, Nev., March 12, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2015, the record date. About PDL BioPharmaPDL manages a portfolio of patents and roy...
INCLINE VILLAGE, Nev., March 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 174.8506 shares of common stock per $1,000 principal amount or approximately $5.72 per share, effective March 3, 2015....
INCLINE VILLAGE, Nev., March 3, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the third of three shareholder lawsuits filed in the fall of 2014, was voluntarily dismissed without prejudice. On February 2, 2015, a securities lawsuit that was filed against the Company last September on behalf...
INCLINE VILLAGE, Nev., Feb. 26, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, May 28, 2015, at 10:00 a.m. Pacific Time for all stockholders of record on April 2, 2015. The meeting will take place at the Hyatt Regency Hotel in In...
INCLINE VILLAGE, Nev., Feb. 23, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2014. Total revenues in 2014 increased 27 percent to $581.2 million from $456.3 million in 2013. Revenues for the year ended December 31, 2014 included $487.5 milli...
INCLINE VILLAGE, Nev., Feb. 17, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2014 financial results for the period ended December 31, 2014, on Monday, February 23, 2015, after market close. PDL's management will host a conference call and webcast that da...
INCLINE VILLAGE, Nev., Feb. 4, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. 2015 BIO CEO & Investor ConferenceMonday, February 9, 20152:00 p.m. ESTNew York, NY 2015 RBC Capi...
INCLINE VILLAGE, Nev., Jan. 29, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid to its stockholders in 2015 will be $0.15 per share of common stock, for a total of $0.60 for the full year. The $0.15 dividends will each be p...
INCLINE VILLAGE, Nev., Dec. 15, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 5, 2014, the record date. About PDL BioPharmaPDL manages a portfolio of patents an...
INCLINE VILLAGE, Nev., Dec. 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2014, of approximately $158 million, as compared with actual revenue of $112 million for the fourth quarter of 2013, an approximate 41 percent increase. The forecasted reven...
INCLINE VILLAGE, Nev., Dec. 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 171.1768 shares of common stock per $1,000 principal amount or approximately $5.84 per share, effective December 3, 201...
INCLINE VILLAGE, Nev., Nov. 18, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that in connection with the acquisition of Durata Therapeutics, Inc. by Actavis, PDL has received approximately $42.7 million in connection with the termination of PDL's credit agreement with Durata, which included repayment of the full pri...
INCLINE VILLAGE, Nev., Nov. 14, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc. (NASDAQ: AXGN).  In October 2012, PDL entered into a structured financ...
INCLINE VILLAGE, Nev., Nov. 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that company management will present at the Jefferies 2014 Global Healthcare Conference next week in London. The presentation, which will be webcast, will occur on November 19, 2014 at 8:40 a.m. London time (3:40 a.m. EST). To access...
INCLINE VILLAGE, Nev., Nov. 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2014. Total revenues for the third quarter of 2014 increased approximately 64 percent to $164.6 million from $100.2 million in the third quarter of 2013. Rev...
INCLINE VILLAGE, Nev., Nov. 6, 2014 /PRNewswire/ -- PDL BioPharma ("PDL") (Nasdaq: PDLI) announced today that it has acquired a portion of the University of Michigan's ("U-M") worldwide royalty interest in Cerdelga™ (eliglustat) for $65.6 million.  Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genz...
INCLINE VILLAGE, Nev., Nov. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2014 financial results for the period ended September 30, 2014, on Monday, November 10, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. ...
INCLINE VILLAGE, Nev., Oct. 8, 2014 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI), today announced the appointment of PricewaterhouseCoopers LLP ("PwC") as its independent registered public accounting firm. PwC will commence work immediately, beginning with their review of our financial results for the three and nine m...
INCLINE VILLAGE, Nev., Oct. 6, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), today announced two enhancements to the company's management team.  Danny Hart, who has served in the position of deputy general counsel, assistant secretary and corporate counsel since 2010, has been appointed to the position of vice president, business d...
INCLINE VILLAGE, Nev., Sept. 23, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI), has been informed of a class action lawsuit filed against the company that alleges violations of federal securities laws. The company disputes the allegations in the complaint and will vigorously defend this lawsuit. "We believe that any claims al...
INCLINE VILLAGE, Nev., Sept. 17, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) was orally notified by its independent registered accounting firm, Ernst & Young LLP ("EY") that it was resigning effective September 11, 2014. The resignation was confirmed in a letter delivered to the Company on September 15, 2014 and reported in PDL's ...
INCLINE VILLAGE, Nev., Sept. 15, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 5, 2014, the record date. About PDL BioPharma PDL BioPharma manages a po...
INCLINE VILLAGE, Nev., Sept. 9, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2014, of approximately $165 million, as compared with actual revenue of $100.2 million for the third quarter of 2013, an approximate 65 percent increase. The forecasted reve...
INCLINE VILLAGE, Nev., Sept. 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the:  3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 167.9812 shares of common stock per $1,000 principal amount or approximately $5.95 per share, effective September 3, ...
INCLINE VILLAGE, Nev., Aug. 18, 2014 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2014. Total revenues for the second quarter of 2014 increased approximately 10 percent to $162.8 million from $148.5 million in the second quarter of 2013. Reven...
INCLINE VILLAGE, Nev., Aug. 18, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will issue its second quarter financial results after market today and has rescheduled its second quarter earnings call to discuss the financial results for tomorrow, Tuesday, August 19, 2014 at 4:30 p.m. EDT. A slide prese...
INCLINE VILLAGE, Nev., Aug. 8, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission (SEC) allowing for a five-day extension to file its Quarterly Report on Form 10-Q for the period ended June 30, 2014. ...
INCLINE VILLAGE, Nev., July 30, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that company management will participate in the Jefferies 2014 Boston Healthcare Summit next week in Boston, Massachusetts. The conference will occur on August 6, 2014 and will not be webcast. About PDL BioPharma, Inc. PDL Bio...
INCLINE VILLAGE, Nev., July 28, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2014 financial results for the period ended June 30, 2014, on Monday, August 11, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Easte...
INCLINE VILLAGE, Nev., June 24, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will participate in the following conferences this week. JMP Securities Healthcare ConferenceWednesday, June 25, 20141:00 p.m. EDTNew York, NYWill be webca...
INCLINE VILLAGE, Nev., June 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2014, the record date. About PDL BioPharma PDL BioPharma manages a portfolio of p...
INCLINE VILLAGE, Nev., June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2014, of approximately $140 million, as compared with actual revenue of $143.6 million for the second quarter of 2013, an approximate 3 percent decrease. The forecasted revenue...
INCLINE VILLAGE, Nev., June 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 165.4367 shares of common stock per $1,000 principal amount or approximately $6.04 per share, effective June 3, 2014...
INCLINE VILLAGE, Nev., May 29, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference next week in New York City.  The presentation, which will be webcast, will occur on Thursday, June ...
INCLINE VILLAGE, Nev., May 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2014. Total revenues for the first quarter of 2014 increased 52 percent to $139.7 million from $91.8 million in the first quarter of 2013. Royalty revenues for the first quarter ...
INCLINE VILLAGE, Nev., May 8, 2014  /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia, the company's vice president and chief financial officer, will present at the Bank of America Merrill Lynch Health Care Conference next week in Las Vegas, Nevada.  The presentation, which will be webcast, will occur on Thur...
INCLINE VILLAGE, Nev., May 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2014 financial results for the period ended March 31, 2014, on Monday, May 12, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Ti...
INCLINE VILLAGE, Nev., May 6, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that two inventors of the company's patented breakthrough  antibody technology have been named as a top-three finalist for the European Patent Office's highly prestigious 2014 European Inventor Award in the "Non-European Countries" category. ...
INCLINE VILLAGE, Nev., April 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has acquired $150 million of Notes due 2029 (the Notes) from Accel 300, LLC, a wholly-owned subsidiary of kaleo, Inc. (formerly known as Intelliject, Inc.) (kaleo). The Notes are backed by 100 percent of royalties from kaleo's first appro...
INCLINE VILLAGE, Nev., March 13, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, May 28, 2014, at 10:00 a.m. Pacific Time for all stockholders of record on April 4, 2014. The meeting will take place at the Hyatt Regency Hotel in Incline Village...
INCLINE VILLAGE, Nev., March 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2014, the record date. About PDL BioPharmaPDL BioPharma manages a portfolio of paten...
INCLINE VILLAGE, Nev., March 11, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase. The forecasted growth ...
INCLINE VILLAGE, Nev., March 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the appointment of David W. Gryska to its board of directors.  Mr. Gryska brings more than 30 years of strategic biopharmaceutical and financial leadership experience to PDL and has demonstrated success in implementing successful strategic...
INCLINE VILLAGE, Nev., March 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 162.7280 shares of common stock per $1,000 principal amount or approximately $6.15 per share, effective March 3, 2014&...
INCLINE VILLAGE, Nev., March 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2013. Total revenues in 2013 increased 18 percent to $442.9 million from $374.5 million in 2012. For the fourth quarter of 2013, total revenues were $110.1 mill...
INCLINE VILLAGE, Nev., Feb. 24, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2013 financial results for the period ended December 31, 2013, on Monday, March 3, 2014, after market close. PDL's management will host a conference call and webcast that day at...
INCLINE VILLAGE, Nev., Feb. 19, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) 2014 RBC Capital Markets' Health...
INCLINE VILLAGE, Nev. and NEW YORK, Feb. 18, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) and Paradigm Spine, LLC, a provider of innovative spinal implant technologies, announced today that the parties have entered into a credit agreement whereby PDL will provide Paradigm with up to $75 million of secured debt financing.  Armentum Partne...
INCLINE VILLAGE, Nev., Feb. 13, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has retained Stephen J. Hoffman, M.D., Ph.D. as senior advisor to the Company, effective as of February 3, 2014. PDL is focused on acquiring income generating assets to continue increasing shareholder value. Dr. Hoffman bri...
INCLINE VILLAGE, Nev., Feb. 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes maturing on February 1, 2018 (2018 Notes).  PDL issued $300 million aggregate principal amount of 2018 Notes, which included $39.13 million aggregate pri...
INCLINE VILLAGE, Nev., Feb. 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $260.87 million aggregate principal amount of its 4.00% Convertible Senior Notes due February 1, 2018 (the Notes) in an underwritten public offering.  The conversion rate of the Notes will initially be 109.1048 sha...
INCLINE VILLAGE, Nev., Feb. 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it entered into exchange and purchase agreements with certain holders of approximately $131.7 million aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (2015 Notes). The exchange agreements provide for t...
INCLINE VILLAGE, Nev., Feb. 5, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of new convertible senior notes due February 1, 2018 (notes) under the Company's shelf registration statement filed with the U.S. Secur...
INCLINE VILLAGE, Nev., Feb. 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BIO CEO and Investor Conference next week in New York City.  The presentation, which will be webcast, will occur on Tuesday, February 11, 2014...
INCLINE VILLAGE, Nev., Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd. (Roche) which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its ...
INCLINE VILLAGE, Nev., Jan. 30, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid to its stockholders in 2014 will be $0.15 per share of common stock, for a total of $0.60 for the full year. In addition, PDL's board of directors, ha...
INCLINE VILLAGE, Nev., Dec. 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 5, 2013, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) ...
INCLINE VILLAGE, Nev., Dec. 10, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2013, of approximately $109 million, as compared with actual revenue of $86 million for the fourth quarter of 2012, an approximate 27 percent increase. (Logo: http://photos...
INCLINE VILLAGE, Nev., Dec. 4, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 159.9165 shares of common stock per $1,000 principal amount or approximately $6.25 per share, effective December 3, 201...
INCLINE VILLAGE, Nev., Dec. 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 25th Annual Piper Jaffray Healthcare Conference in New York tomorrow, Tuesday, December 3, 2013 at 3:00 p.m. Eastern Time. (...
INCLINE VILLAGE, Nev., Nov. 7, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Credit Suisse 2013 Healthcare Conf...
INCLINE VILLAGE, Nev., Nov. 6, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Total revenues for the third quarter of 2013 increased 14 percent to $97.3 millio...
INCLINE VILLAGE, Nev., Nov. 6, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it closed a financing transaction with Durata Therapeutics, Inc. (NASDAQ: DRTX), a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. ...
INCLINE VILLAGE, Nev., Nov. 5, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has entered into a debt financing transaction with Direct Flow Medical, Inc. (DFM), a transcatheter heart valve innovator focused on improving patient outcomes.  PDL will provide a total of up to $50 million to DFM to be use...
INCLINE VILLAGE, Nev., Oct. 28, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2013 financial results for the period ended September 30, 2013, on Wednesday, November 6, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p....
INCLINE VILLAGE, Nev., Oct. 21, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash payment. PDL will receive all royalty and milestone pa...
INCLINE VILLAGE, Nev., Oct. 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it closed a financing transaction with LENSAR, Inc., a leader in next-generation femtosecond laser technology for refractive cataract surgery, in which PDL will provide LENSAR with up to $60 million of debt financing, as part of an $87 ...
INCLINE VILLAGE, Nev., Sept. 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 5, 2013, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF5...
INCLINE VILLAGE, Nev., Sept. 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 4th Annual Credit Suisse Small/Mid Cap Conference in New York City on Tuesday, September 17, 2013. Presentations at this conferenc...
INCLINE VILLAGE, Nev., Sept. 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase. (Logo: http://photos.p...
INCLINE VILLAGE, Nev., Sept. 4, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is 157.3700 shares of common stock per $1,000 principal amount or approximately $6.35 per share, effective September 3, 2...
INCLINE VILLAGE, Nev., Aug. 8, 2013  /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Royalty revenues for the second quarter of 2013 increased 14 percent to $143.6 millio...
INCLINE VILLAGE, Nev., Aug. 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2013 financial results for the period ended June 30, 2013, on Thursday, August 8, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Easte...
INCLINE VILLAGE, Nev., July 24, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed David Montez, CPA, as controller and chief accounting officer.  Mr. Montez's appointment is effective as of today.  (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) "Dave brings m...
INCLINE VILLAGE, Nev., June 25, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Glenn M. Reicin as senior advisor to the company, effective as of July 1st.  PDL is focused on acquiring income generating assets to continue increasing shareholder value, and Mr. Reicin will focus on bolsteri...
INCLINE VILLAGE, Nev., June 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2013, the record date. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) ...
INCLINE VILLAGE, Nev., June 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2013, of approximately $143 million, as compared with actual royalty revenue of $126 million for the second quarter of 2012, an approximate 14 percent increase. (Logo:...
INCLINE VILLAGE, Nev., June 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that on June 7, 2013, the Company filed a Notice of Arbitration against Genentech with the American Arbitration Association in Voorhees, New Jersey, alleging, inter alia, that Genentech underpaid royalties going back to at least 2007 and im...
INCLINE VILLAGE, Nev., June 3, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 176.389 shares of common stock per $1,000 principal amount or approximately $5.67 per share, effective June ...
INCLINE VILLAGE, Nev., May 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Jefferies 2013 Global Healthcare...
INCLINE VILLAGE, Nev., May 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2013. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Royalty revenues for the first quarter of 2013 increased 19 percent over the same period of 2012. Tot...
INCLINE VILLAGE, Nev., May 2, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2013 financial results for the period ended March 31, 2013, on Thursday, May 9, 2013, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern T...
INCLINE VILLAGE, Nev., April 30, 2013  /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Peter S. Garcia to the position of vice president, chief financial officer (CFO) and acting chief accounting officer, effective as of May 13, 2013.  Mr. Garcia has spent the last 16 years in various CFO posi...
INCLINE VILLAGE, Nev., April 22, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) and Avinger, Inc. announced today that they closed a structured financing and royalty transaction on April 18, 2013, in which PDL will provide Avinger with up to $40 million of financing.  (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808...
INCLINE VILLAGE, Nev., March 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 5, 2013, the record date. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOG...
INCLINE VILLAGE, Nev., March 11, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2013, of approximately $92 million, as compared with actual royalty revenue of $77 million for the first quarter of 2012, a 19 percent increase. (Logo: http://photos.p...
INCLINE VILLAGE, Nev., March 6, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Tuesday, May 21, 2013, at 10:00 a.m. Pacific Time for all stockholders of record on March 28, 2013. The meeting will take place at the Hyatt Regency Hotel in Incline Village,...
INCLINE VILLAGE, Nev., March 4, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 173.200 shares of common stock per $1,000 principal amount or approximately $5.77 per share, effective Marc...
INCLINE VILLAGE, Nev., March 1, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2012. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Total revenues in 2012 were $374.5 million, compared to $362.0 million in 201...
INCLINE VILLAGE, Nev., Feb. 25, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2012 financial results for the period ended December 31, 2012, on Friday, March 1, 2013, after market close. PDL's management will host a conference call and webcast that day at...
INCLINE VILLAGE, Nev., Feb. 20, 2013  /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. RBC Capital Markets Healthcare Conference Wednesday, February 27, 2013 9:00 a.m. ET New York City ...
INCLINE VILLAGE, Nev., Jan. 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid to its stockholders in 2013 will be $0.15 per share of common stock.  The $0.15 dividends will each be paid on March 12, June 12, September 12 and Dec...
INCLINE VILLAGE, Nev., Jan. 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Caroline Krumel resigned her position as vice president of finance and principal accounting officer effective immediately on January 25th. Ms. Krumel did not advise the Company of any disagreements over any matter of accounting princip...
INCLINE VILLAGE, Nev., Jan. 3, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 31st Annual JP Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2013 at 9:30 a.m. Pacific Time. (Logo:...
INCLINE VILLAGE, Nev., Dec. 17, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 7, 2012, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF5580...
INCLINE VILLAGE, Nev., Dec. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the fourth quarter ending December 31, 2012, of approximately $86 million, as compared with actual royalty revenue of $73 million for the fourth quarter of 2011, an 18 percent increase.  Total anticipated revenue...
INCLINE VILLAGE, Nev., Dec. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 169.525 shares of common stock per $1,000 principal amount or approximately $5.90 per share, effective Decem...
INCLINE VILLAGE, Nev., Dec. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Bruce Tomlinson has resigned his position as vice president and chief financial officer of PDL due to personal reasons.  His resignation is effective as of November 30, 2012.  The company will begin a search for a new CFO. (Logo...
INCLINE VILLAGE, Nev., Nov. 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 4:30 p.m. ET in New York City. (Log...
INCLINE VILLAGE, Nev., Nov. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Royalty revenues for the third quarter of 2012 increased two percent to $85.2 mill...
INCLINE VILLAGE, Nev., Nov. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the completion of a structured financing transaction with Wellstat Diagnostics, LLC in which PDL loaned Wellstat $40 million to be used by Wellstat in its development and commercialization of small point of care diagnostic systems that can p...
INCLINE VILLAGE, Nev., Nov. 1, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2012, on Monday, November 5, 2012, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Easter...
INCLINE VILLAGE, Nev., Oct. 9, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) and AxoGen, Inc. (OTCBB: AXGN) announced today that they closed a structured financing transaction on October 5, 2012, in which PDL provided AxoGen with an aggregate of $20.8 million in exchange for royalties on certain AxoGen revenues.  AxoGen is a regener...
INCLINE VILLAGE, Nev., Sept. 14, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 7, 2012, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF5...
INCLINE VILLAGE, Nev., Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Rodman and Renshaw Annual Globa...
INCLINE VILLAGE, Nev., Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the third quarter ending September 30, 2012, of approximately $85 million, as compared with actual royalty revenue of $83 million for the third quarter of 2011, a two percent increase.  (Logo: http://pho...
INCLINE VILLAGE, Nev., Sept. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 166.264 shares of common stock per $1...
INCLINE VILLAGE, Nev., Aug. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Royalty revenues for the second quarter of 2012 increased three percent to $125.9 milli...
INCLINE VILLAGE, Nev., July 19, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2012, on Thursday, August 2, 2012, after the market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Easte...
INCLINE VILLAGE, Nev., June 19, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Genentech has notified PDL that Pertuzumab, brand name Perjeta®, is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter following the first quarter of Perjeta sales in accordance with Genentech's lice...
INCLINE VILLAGE, Nev., June 14, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 7, 2012, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO )...
INCLINE VILLAGE, Nev., June 13, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the second quarter ending June 30, 2012, of approximately $125 million, as compared with actual royalty revenue of $122 million for the second quarter of 2011, a two percent increase.  (Logo:  http://pho...
INCLINE VILLAGE, Nev., June 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 162.885 shares of common stock per $1,...
INCLINE VILLAGE, Nev., June 4, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6, 2012, at 4:00 p.m. ET in New York City. (Logo: http://photo...
INCLINE VILLAGE, Nev., May 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences: (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Eleventh Annual JMP Secu...
INCLINE VILLAGE, Nev., May 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Royalty revenues for the first quarter of 2012 increased five percent over the same period of 2011. Tot...
INCLINE VILLAGE, Nev., April 27, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter financial results for the period ended March 31, 2012 on Thursday, May 3, 2012 after the markets close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern ...
INCLINE VILLAGE, Nev., April 26, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Bruce Tomlinson to the position of vice president and chief financial officer effective as of June 11, 2012.  Mr. Tomlinson brings more than 20 years of financial leadership experience to PDL and joins the co...
INCLINE VILLAGE, Nev., April 12, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Tuesday, June 5, 2012, at 10:00 a.m. Pacific Time for all stockholders of record on April 13, 2012. The meeting will take place at the Hyatt Regency Hotel in Incline Village,...
INCLINE VILLAGE, Nev., March 14, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 14, 2012, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of March 7, 2012, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)...
INCLINE VILLAGE, Nev., March 8, 2012 /PRNewswire/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the first quarter ending March 31, 2012, of approximately $77 million, as compared with actual royalty revenue of $73 million for the first quarter of 2011, a five percent increase.  Total revenue for the first q...
INCLINE VILLAGE, Nev., March 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 159.098 shares of common stock per $1,000 principal amount or approximately $6.29 per share, effective Marc...
INCLINE VILLAGE, Nev., Feb. 23, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2011. (Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Total revenues in 2011 were $362 million, compared to $345 million in 2010, with royalty ...
INCLINE VILLAGE, Nev., Feb. 21, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences: (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) RBC Capital Markets G...
INCLINE VILLAGE, Nev., Feb. 16, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year financial results for the period ended December 31, 2011 on Thursday, February 23, 2012 after market close. PDL's management will host a conference call and webcast that day at ...
INCLINE VILLAGE, Nev., Feb. 7, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference on Monday, February 13, 2012, at 1:00 p.m. ET in New York City. (Logo:  http://phot...
INCLINE VILLAGE, Nev., Feb. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it has retired $10,028,000 aggregate principal amount of the Company's 2.875% Convertible Senior Notes due February 15, 2012 (the Old Notes). Pursuant to ...
INCLINE VILLAGE, Nev., Jan. 24, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its board of directors has declared that the regular, quarterly dividends to be paid to its stockholders in 2012 will be $0.15 per share of common stock.  The $0.15 dividends will each be paid on March 14, June 14, September 14 and Dec...
INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible...
INCLINE VILLAGE, Nev., Jan. 5, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 30th Annual JP Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2012 at 9:30 a.m. Pacific time. (Logo:...
INCLINE VILLAGE, Nev., Jan. 3, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the expiration and preliminary results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Conve...
INCLINE VILLAGE, Nev., Dec. 19, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million, as compared with actual results of $76 million for the fourth quarter of 2010, a five percent decrease. Total anticipated revenue for the year en...
INCLINE VILLAGE, Nev., Dec. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 8, 2011, the record date. (Logo: http://photos.prnewswire.com/prnh/20110822/SF5580...
INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Christine Larson has resigned her position as vice president and chief financial officer of PDL effective as of December 9, 2011.  The company will immediately begin a search for a new CFO. (Logo:  http://photos.prnewswire.com/...
INCLINE VILLAGE, Nev., Dec. 12, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today corrected its earlier-announced adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), to 155.396 shares of common stock per $1,000 principal amount, reflecting a conversion price of ...
INCLINE VILLAGE, Nev., Dec. 7, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for its: 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes) is 155.354 shares of common stock per $1,000 principal amount or approximately $6.44 per share, effective Decem...
INCLINE VILLAGE, Nev., Nov. 15, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has commenced an offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2011 Convertible Senio...
INCLINE VILLAGE, Nev., Nov. 9, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Revenues Total revenues for the third quarter of 2011 were $83.8 million, compared to $86.4 million for...
INCLINE VILLAGE, Nev., Nov. 8, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference next week in New York City.  The presentation will begin at 10 a.m. EST on Tuesday, Nov...
INCLINE VILLAGE, Nev., Nov. 2, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2011, on Wednesday, November 9, 2011, after the markets close. PDL's management will host a conference call and webcast that day at 4:30 p.m...
INCLINE VILLAGE, Nev., Oct. 19, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has retained Franklin M. Berger, C.F.A., and Evan Bedil, M.D., as advisors to the Company to assist with the identification and evaluation of royalty bearing asset acquisitio...
INCLINE VILLAGE, Nev., Sept. 15, 2011 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 8, 2011, the record date. About PDL BioPharmaPDL pio...
INCLINE VILLAGE, Nev., Sept. 13, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. (Logo: ...
INCLINE VILLAGE, Nev., Sept. 8, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2011, of approximately $83 million, as compared with actual results of ...
INCLINE VILLAGE, Nev., Sept. 7, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced adjustments to the conversion rates for: The 2.875% Convertible Senior Notes due February 15, 2015 (the February ...
INCLINE VILLAGE, Nev., July 27, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2011. Total revenues for the second quarter of 2011 were $122.1 million, compared to ...
INCLINE VILLAGE, Nev., July 20, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2011, on Wednesday, July 27, 2011, after the markets clo...
INCLINE VILLAGE, Nev., July 11, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and ...
INCLINE VILLAGE, Nev., July 5, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has completed the retirement of the remaining $133.5 million in aggregate principal of the Company's 2.00% Convertible Senior Notes, due February 15, 2012...
INCLINE VILLAGE, Nev., June 16, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of ...
INCLINE VILLAGE, Nev., June 9, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 mill...
INCLINE VILLAGE, Nev., June 6, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced an adjustment to the conversion rate for: The 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes), effective ...
INCLINE VILLAGE, Nev., June 1, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2011, of approximately $128 million, as compared with actual results of $12...
INCLINE VILLAGE, Nev., May 24, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that on June 30, 2011, it will redeem all of the Company's outstanding 2.00% Convertible Senior Notes due February 15, 2012 (the Notes). Holders of the N...
INCLINE VILLAGE, Nev., May 16, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has completed the issuance of $155.25 million in aggregate principal amount of its 3.75% Convertible Senior Notes due May 2015 (the "Notes") in a...
INCLINE VILLAGE, Nev., May 10, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced it has agreed to sell $135.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due May 2015 (the "Notes") in an underwritten ...
INCLINE VILLAGE, Nev., May 9, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: PDLI) today announced that it intends to offer, subject to market and other conditions, $135 million aggregate principal amount of new convertible senior notes due May 2015...
INCLINE VILLAGE, Nev., May 3, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences: ...
INCLINE VILLAGE, Nev., April 27, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2011. Total revenues for the first quarter of 2011 were $83.3 million, compared to ...
INCLINE VILLAGE, Nev., April 20, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter financial results for the period ended March 31, 2011 on Wednesday, April 27, 2011 after the markets clo...
INCLINE VILLAGE, Nev., April 18, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. Pacific Time for all stockholders of record on ...
INCLINE VILLAGE, Nev., March 8, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) and its 2.875% Convertible Senior Notes due February...
INCLINE VILLAGE, Nev., March 7, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the first quarter ending March 31, 2011 of approximately $83 million, as compared with actual results of $62 ...
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that its board of directors has adopted a regular dividend policy for 2011 and beyond and declared that the four quarterly dividends to be paid to its stockholders in 2011 will be $0.15 per ...
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that the Technical Board of Appeal of the European Patent Office (EPO) has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's European Patent No. 0 451 216B (the '216B Patent) ...
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has entered into a definitive settlement agreement with Novartis that resolves all disputes between them. Under the settlement agreement, PDL agreed to dismiss its claims against Novartis in its action in ...
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2010. Total revenues in 2010 were $345.0 million, compared to ...
INCLINE VILLAGE, Nev., Feb. 24, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences: ...
INCLINE VILLAGE, Nev., Feb. 22, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its fourth quarter and full year financial results for the period ended December 31, 2010 on Monday, February 28, 2011 afte...
GAITHERSBERG, Md. and INCLINE VILLAGE, Nev., Feb. 16, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis...
BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire via COMTEX/ --UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between t...
INCLINE VILLAGE, Nev., Jan. 25, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Caroline Krumel, CPA to the position of vice president of finance and chief accounting officer, effective January 31, 2011. Ms. Krumel will ...
INCLINE VILLAGE, Nev., Jan. 10, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on January 7, 2011, the United States District Court for the Northern District of California issued summary judgment order deciding certain issues favor...
INCLINE VILLAGE, Nev., Jan. 5, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 29th Annual JP Morgan Healthcare Conference in S...
INCLINE VILLAGE, Nev., Dec. 20, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on December 15, 2010, the U.S. Patent and Trademark Office (the PTO) terminated its interference proceeding between certain claims of the Company's Queen et al., U.S. Patent No. 5,585,0...
INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2010 of approximately $74 million, as compared with actual results of $58.3 million for the fourth quarter of 2009, a 27 percent year-over-year increase. The gro...
INCLINE VILLAGE, Nev., Nov. 10, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2010. Financial Results for the Third Quarter Ended September 30, 2010 Revenues for the third quarter of 2010 wer...
INCLINE VILLAGE, Nev., Nov. 5, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the exchange of $92.0 million in aggregate principal of the Company's outstanding 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) in separate, privately negotiated exchange tran...
INCLINE VILLAGE, Nev., Nov. 2, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its third quarter financial results on Wednesday, November 10, 2010 after the markets close. PDL's management will host a conference call and webcast at 4:30 p.m. Eastern Time to discu...
INCLINE VILLAGE, Nev., Oct 28, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that management is scheduled to present at the following upcoming investor conferences. ...
INCLINE VILLAGE, Nev., Oct 27, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL, the Company) (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated exchange agreements under which it will retire $92.0 million in aggregate principal of the Company's outstanding 2.00% Convertible Senior Notes du...
INCLINE VILLAGE, Nev., Oct 04, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the October 1, 2010 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as of September 15, 2010, the record date. As previously announced, the conversion rate f...
INCLINE VILLAGE, Nev., Sept 16, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the retirement of the remaining $54.3 million in aggregate principal of the Company's 2.75% Convertible Subordinated Notes, due August 16, 2023 (the "2023 Notes") in exchange for 8.9 million shares ...
INCLINE VILLAGE, Nev., Sept 15, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming conferences. UBS Global Life Sciences Conference Tuesday, September 21,...
INCLINE VILLAGE, Nev., Sept 13, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all...
INCLINE VILLAGE, Nev., Sept 10, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) affirmed that on September 15, 2010 it will redeem all of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 (the "2023 Notes"). Holders of the 2023 Notes have been provided notice of the redemption by t...
INCLINE VILLAGE, Nev., Sept 09, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established September 13, 2010 as the ex-dividend date for its second of two special dividends to stockholders declared by the Board of Directors on January 27, 2010. The dividend of $0.50 per shar...
INCLINE VILLAGE, Nev., Sept 01, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase. The gro...
INCLINE VILLAGE, Nev., Aug 13, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today it has received a facsimile letter from Genentech asserting that Avastin®, Herceptin®, Lucentis® and Xolair...
INCLINE VILLAGE, Nev., Aug 12, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the retirement of $61.7 million in aggregate principal amount of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 (the "2023 Notes") for consideration consisting of...
INCLINE VILLAGE, Nev., Aug 11, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that Christine Larson, the company's vice president and chief financial officer, will present at the 2010 Global Hunter Securities Healthcare Conference in Newport Beach, California on August 17, 2010 at 4:00 P.M. Pacific...
INCLINE VILLAGE, Nev., Aug 05, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has entered into separate privately negotiated agreements under which it will retire $61.6 million in aggregate principal amount of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 20...
INCLINE VILLAGE, Nev., July 29, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the BMO Capital Markets' 10th Annual Focus on Healthcare Conference in New York City on August 5, 2010 at 10:15 A.M. Eastern T...
INCLINE VILLAGE, Nev., July 28, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter ended June 30, 2010. "Our licensed products continue to generate substantial clinical interest. In early July, Roche and Genentech announced that they have filed a Biolog...
INCLINE VILLAGE, Nev., July 20, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its second quarter financial results on Wednesday, July 28, 2010 after the markets close. PDL's management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss...
INCLINE VILLAGE, Nev., June 15, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the second quarter ended June 30, 2010 of approximately $120 million, as compared with actual results of $125.9 million for the second quarter of 2009. Included in second quarter 2010 guidance is $1.5 mill...
INCLINE VILLAGE, Nev., May 4, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Ninth Annual JMP Securities Research Conference in San Francisco on Wednesday, May 12, 2010 at 9:00 a.m. Pacific Time. To...
INCLINE VILLAGE, Nev., April 29, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2010. Total revenues for the first quarter of 2010 were $62.1 million, compared with $62.6 million for the same period of 2009. Due to ongoing legal disputes wit...
INCLINE VILLAGE, Nev., April 22, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will hold a conference call and webcast on Thursday, April 29 at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2010. The call and webcast will follow the release of the first qu...
INCLINE VILLAGE, Nev., April 5, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the April 1, 2010 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as of March 15, 2010, the Record Date. As previously announced, the conversion rate for the Compa...
INCLINE VILLAGE, Nev., March 24, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the cost basis for shares of Facet Biotech Corporation (Facet) (Nasdaq: FACT) distributed to PDL stockholders is $13.00, based on the closing price on the first day that Facet traded, December 19, 2008. On December 18, ...
INCLINE VILLAGE, Nev., March 16, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time for all stockholders of record on April 15, 2010. The meeting will take place at the Hyatt Regency Hotel in Inc...
INCLINE VILLAGE, Nev., March 15, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced adjustments to the conversion rates for its 2.00% Convertible Senior Notes due February 15, 2012 (the "2012 Notes") and its 2.75% Convertible Subordinated Notes due August 16, 2023 (the "2023 Notes") effective March 16, 2010 ...
INCLINE VILLAGE, Nev., March 3, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference in Boston on Tuesday, March 9, 2010 at 1:30 p.m. Eastern Time. To acces...
INCLINE VILLAGE, Nev., March 2, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2009. Total revenues from continuing operations in 2009 were $318.2 million, an eight percent increase from $294.2 million in 2008. For the fourth qu...
INCLINE VILLAGE, Nev., Feb 22, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold a conference call and webcast on Tuesday, March 2 at 4:30 p.m. Eastern Time to discuss its financial results for the fourth quarter and full year 2009, and provide a business update. The call and web...
INCLINE VILLAGE, Nev., Feb 02, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8, 2010 at 2:00 p.m. Eastern Time. To acc...
INCLINE VILLAGE, Nev., Jan 28, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay two special dividends to its stockholders in 2010. Each of the dividends will be $0.50 per share. The first special dividend will be paid on April 1, 2010 to all stockholders who own shares of PDL on March 15,...
INCLINE VILLAGE, Nev., Jan 21, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) today announced the allocation between dividend income and return of capital for federal income tax purposes for dividends paid in 2009. In 2009, PDL made two cash distributions of $0.50 per share of common stock on April 1, 2009 and October 1, 20...
Page:
...
Next Last
 
= add release to Briefcase